Leerink Partnrs Expects Increased Earnings for Certara

Certara, Inc. (NASDAQ:CERT) – Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for Certara in a report released on Monday, April 14th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.29 per share for the year, up from their previous forecast of $0.27. The consensus estimate for Certara’s current full-year earnings is $0.28 per share.

A number of other brokerages have also weighed in on CERT. Robert W. Baird lifted their price target on shares of Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. William Blair restated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Barclays decreased their price objective on Certara from $13.00 to $11.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. KeyCorp upped their price target on Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Stephens reissued an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Certara currently has an average rating of “Moderate Buy” and a consensus target price of $15.17.

Certara Trading Down 2.5 %

NASDAQ:CERT opened at $13.53 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The business’s 50-day simple moving average is $11.62 and its 200-day simple moving average is $11.43. Certara has a fifty-two week low of $8.64 and a fifty-two week high of $17.94. The stock has a market capitalization of $2.18 billion, a PE ratio of -67.65, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64.

Institutional Investors Weigh In On Certara

Institutional investors and hedge funds have recently made changes to their positions in the stock. Blue Trust Inc. raised its position in Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after acquiring an additional 822 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Certara by 3.6% in the 4th quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company’s stock valued at $253,000 after purchasing an additional 823 shares during the period. Wells Fargo & Company MN lifted its stake in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after purchasing an additional 1,047 shares during the last quarter. Bank of Montreal Can increased its position in Certara by 9.1% during the fourth quarter. Bank of Montreal Can now owns 19,943 shares of the company’s stock worth $212,000 after buying an additional 1,670 shares during the last quarter. Finally, Versant Capital Management Inc raised its stake in Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock valued at $27,000 after buying an additional 1,866 shares during the period. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.